Quince Therapeutics (QNCX) Accounts Payables (2018 - 2026)
Quince Therapeutics (QNCX) posted quarterly Accounts Payables of $5.4 million for Q1 2026, up 79.26% year-over-year from $3.0 million in Q1 2025, and up 142.56% quarter-over-quarter from $2.2 million in Q4 2025.
Quince Therapeutics (QNCX) Accounts Payables (2018 - 2026) Analysis & Trends
Quince Therapeutics' Accounts Payables history runs 9 years deep, the most recent figure standing at $5.4 million for Q1 2026.
- In Q1 2026, Accounts Payables rose 79.26% year-over-year to $5.4 million; the TTM figure through Mar 2026 stood at $5.4 million (up 79.26% YoY), while the FY2025 annual figure was $2.2 million, down 23.42% from the prior year.
- Accounts Payables for Q1 2026 stood at $5.4 million, up from $2.2 million in the prior quarter.
- The five-year high for Accounts Payables was $5.4 million in Q1 2026, with the low at $353000.0 in Q2 2023.
- The 5-year median for Accounts Payables is $2.0 million (2023), against an average of $2.2 million.
- The sharpest annual moves came in 2022 and 2024: Accounts Payables sank 88.39% in 2022, then surged 581.3% in 2024.
- Quince Therapeutics' Accounts Payables stood at $570000.0 in 2022, then soared by 256.67% to $2.0 million in 2023, then surged by 42.79% to $2.9 million in 2024, then retreated by 23.42% to $2.2 million in 2025, then jumped by 142.56% to $5.4 million in 2026.
- Business Quant data shows QNCX's Accounts Payables at $5.4 million in Q1 2026, $2.2 million in Q4 2025, and $3.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - | 4.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.39 Mn |
| Dec 31, 2025 | 2.22 Mn |
| Sep 30, 2025 | 3.40 Mn |
| Jun 30, 2025 | 1.76 Mn |
| Mar 31, 2025 | 3.01 Mn |
| Dec 31, 2024 | 2.90 Mn |
| Sep 30, 2024 | 1.62 Mn |
| Jun 30, 2024 | 2.41 Mn |
| Mar 31, 2024 | 2.07 Mn |
| Dec 31, 2023 | 2.03 Mn |
| Sep 30, 2023 | 409,000.00 |
| Jun 30, 2023 | 353,000.00 |
| Mar 31, 2023 | 1.65 Mn |
| Dec 31, 2022 | 570,000.00 |
| Sep 30, 2022 | 1.18 Mn |
| Jun 30, 2022 | 1.87 Mn |
| Mar 31, 2022 | 3.73 Mn |
| Dec 31, 2021 | 4.91 Mn |
| Sep 30, 2021 | 2.88 Mn |
| Jun 30, 2021 | 7.19 Mn |